GoodRx Holdings Stock News

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., is riding into new creative territory with the launch of The Savings Wrangler, a groundbreaking brand campaign that aims to bring the company's mission to life in an unforgettable way. Designed to deepen cultural relevance and brand resonance, the campaign introduces a lasso-wi...

Goodrx Holdings Inc (NASDAQ: GDRX) closed roughly 50% higher on August 18th after Bagsværd-headquartered Novo Nordisk (NYSE: NVO) announced a GLP-1 partnership with the healthcare platform. According to the companies' joint press release today, “all strengths of Ozempic and Wegovy are now available to eligible self-paying patients for $499/month through GoodRx.

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing, driving a 30% stock surge and validating its business model. Pharma Manufacturer Solutions is growing 30%+ annually, boosting profitability and positioning GoodRx as a key player as drug pricing shifts to point-of-sale affordability. Despite headwinds like Rite Aid's bankruptcy an...

Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy.

Novo Nordisk (NYSE:NVO) shares moved higher on Monday after it was announced that US patients can access its diabetes drug Ozempic at a cheaper price through several platforms, expanding access to the therapy for those who do not have insurance coverage.  Patients can pay $499 in cash per month through the drug's website, Novo Nordisk's patient assistance program, the company's direct-to-consum...

GoodRx announces a collaboration with Novo Nordisk to make Ozempic cheaper for self-paying patients.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today. This collaboration significantly lowers the pric...

GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Aubrey Reynolds - Director of Investor Relations Christopher A. McGinnis - CFO & Treasurer Wendy Barnes - President, CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division Daniel R.